autologous dntgf-brii-armored anti-gpc3 car t-cells azd5851
autologous dntgf-brii-armored anti-gpc3 car t-cells azd5851: 1 clinical trial tracked.
autologous dntgf-brii-armored anti-gpc3 car t-cells azd5851 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
What is verified about autologous dntgf-brii-armored anti-gpc3 car t-cells azd5851, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA
Primary endpoint: 1. Incidence of participants with dose-limiting toxicities (DLTs), adverse events (AEs), including adverse events of special interest (AESI) and serious adverse events (SAEs). Determination of the recommended dose of AZD5851 for expansion phase